Patents Assigned to Ceramide Therapeutics
  • Anti-ceramide antibodies
    Patent number: 11447572
    Abstract: Monoclonal antibodies directed to ceramide that inhibit apoptosis are disclosed. Humanized and scFv versions of the antibodies are also disclosed. Methods for prevention or treatment of apoptosis in a subject by administration of the anti-ceramide antibodies are disclosed.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: September 20, 2022
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, CERAMIDE THERAPEUTICS
    Inventors: Jimmy Rotolo, Richard Kolesnick
  • ANTI-CERAMIDE ANTIBODIES
    Publication number: 20190389970
    Abstract: Monoclonal antibodies directed to ceramide that inhibit apoptosis are disclosed. Humanized and scFv versions of the antibodies are also disclosed. Methods for prevention or treatment of apoptosis in a subject by administration of the anti-ceramide antibodies are disclosed.
    Type: Application
    Filed: September 11, 2019
    Publication date: December 26, 2019
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, CERAMIDE THERAPEUTICS
    Inventors: Jimmy ROTOLO, Richard KOLESNICK
  • Anti-ceramide antibodies
    Patent number: 10450385
    Abstract: Monoclonal antibodies directed to ceramide that inhibit apoptosis are disclosed. Humanized and scFv versions of the antibodies are also disclosed. Methods for prevention or treatment of apoptosis in a subject by administration of the anti-ceramide antibodies are disclosed.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: October 22, 2019
    Assignees: Memorial Sloan Kettering Cancer Center, Ceramide Therapeutics
    Inventors: Jimmy Rotolo, Richard Kolesnick